CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026
New preclinical data demonstrate robust weight reduction, lean mass preservation, durable effects after treatment discontinuation and potential for extended dosing intervals SHANGHAI, China — CicadaBio today announced that new preclinical…